.It is actually an extraordinarily busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and...
.Atea Pharmaceuticals' antiviral has failed another COVID-19 trial, but the biotech still holds out ...
.Neurocrine Biosciences' mental illness course pivot has failed. The biotech was incapable to replic...
.Sanofi has actually brought in an overdue entry to the radioligand event, spending one hundred mill...
.After F2G's first try to acquire a brand-new course of antifungal to market was actually thwarted d...
.Moderna has sworn to reduce R&D investing through $1.1 billion by 2027. The choice to retract th...
.Only four months after Sanofi bet $80 million in beforehand cash money on Fulcrum Rehabs' losmapimo...
.Cancer firm Oncternal Therapies is folding all its own medical trials and giving up workers, switch...
.Roche is storing out chances that its own injectable obesity possibility could inevitably illustrat...
.Novo Nordisk has lifted the lid on a period 1 trial of its oral amylin and GLP-1 receptor co-agonis...